

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 1430-245

DENNLER et al.

C# M#

Serial No. 09/601,534

Group Art Unit: 1642

Filed: August 28, 2000

Examiner: Rawlings, S.

Title: METHOD OF SCREENING THERAPEUTIC AGENTS

Date: January 4, 2002

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

## AMENDMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

## Fees are attached as calculated below:

|  |    |                      |              |         |
|--|----|----------------------|--------------|---------|
| Total effective claims after amendment | 21 | minus highest number |              |         |
| previously paid for                    | 21 | (at least 20) =      | 0 x \$ 18.00 | \$ 0.00 |

|                                    |    |                      |              |         |
|------------------------------------|----|----------------------|--------------|---------|
| Independent claims after amendment | 10 | minus highest number |              |         |
| previously paid for                | 10 | (at least 3) =       | 0 x \$ 84.00 | \$ 0.00 |

|  |         |
|--|---------|
| If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) | \$ 0.00 |
|--|---------|

|  |         |
|--|---------|
| Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months) | \$ 0.00 |
|--|---------|

|   |         |
|---|---------|
| Terminal disclaimer enclosed, add \$ 110.00 | \$ 0.00 |
|---|---------|

|   |         |
|---|---------|
| <input type="checkbox"/> First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) | \$ 0.00 |
| <input type="checkbox"/> Please enter the previously unentered, filed   |         |
| <input type="checkbox"/> Submission attached  |         |

**Subtotal \$ 0.00**

|  |          |
|--|----------|
| If "small entity," then enter half (1/2) of subtotal and subtract  | -\$ 0.00 |
| <input type="checkbox"/> Applicant claims "small entity" status. <input type="checkbox"/> Statement filed herewith |          |

|  |         |
|--|---------|
| Rule 56 Information Disclosure Statement Filing Fee (\$180.00) | \$ 0.00 |
|--|---------|

|                                    |         |
|------------------------------------|---------|
| Assignment Recording Fee (\$40.00) | \$ 0.00 |
|------------------------------------|---------|


|  |      |
|--|------|
| Other: SEQUENCE LISTING ALONG WITH FLOPPY DISK IN COMPUTER READABLE FORM | 0.00 |
|--|------|

**TOTAL FEE ENCLOSED \$ 0.00**

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
GRT:ap

NIXON & VANDERHYE P.C.  
By Atty: Gary R. Tanigawa, Reg. No. 43,180

Signature: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

DENNLER et al.

Appln. No. 09/601,534

Filed: August 28, 2000

FOR: METHOD OF SCREENING THERAPEUTIC AGENTS

Atty. Ref.: 1430-245

Group Art Unit: 1642

Examiner: S. Rawlings



AMENDMENT

January 4, 2002

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In reply to the Office Action (Paper No. 16) mailed December 6, 2001, entry and consideration of the following amendments and remarks are respectfully requested.

IN THE SPECIFICATION

Kindly enter the following paragraphs.

Replace the paragraph on page 18, starting on line 6, with:

C1 CAGA boxes containing oligonucleotides (SEQ ID NOS:6-9, respectively):

Replace the paragraph on page 18, starting on line 11, with:

C2 CAGA mutant oligonucleotide (SEQ ID NOS:10-11, respectively):

Replace the paragraph on page 20, starting on line 15, with:

C3 Oligonucleotides were end-labeled with [ $\alpha$ -<sup>33</sup>P]dCTP and [ $\alpha$ -<sup>33</sup>P]dATP using the Klenow fragment of DNA polymerase. Binding reactions containing 10  $\mu$ g of nuclear extracts or 400 ng of GST-Smad proteins or 16  $\mu$ L of *in vitro* translated Smad proteins and 2 ng of labeled oligonucleotides were performed for 20 min at 37°C in 18  $\mu$ L of binding buffer (20 mM HEPES pH 7.9, 30 mM KCl, 4 mM MgCl<sub>2</sub>, 0.1 mM EDTA, 0.8 mM NaPi, 20% glycerol, 4 mM spermidine, 3  $\mu$ g poly dl-dC). Protein-DNA complexes were resolved in